Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants

Hemogenyx Pharmaceuticals PLC


Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants

Monday, May 18, 2020 6:20 AM

LONDON, UK / ACCESSWIRE / May 18, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that, pursuant to the receipt of a warrant exercise notice, it has issued and allotted 668,000 ordinary shares of 1p each in the Company at an exercise price of 5.25p per share for a total consideration of £35,070.

Application will be made for the new Ordinary Shares to be admitted to trading on the Official List of the UK Listing Authority by way of a Standard Listing ('Admission'). The Shares will rank pari passu in all respects with the existing shares. Admission is expected to occur on or around 22 May 2020.

Total Voting Rights

Following Admission, the Company will have 397,921,969 ordinary shares of £0.01 each in issue with voting rights. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Non-Executive Director

 
   

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

 
   

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC


SHARE ARTICLE